• About
• Links
• Contact
• Sitemap

Cancer Therapeutics: The Worldwide Market

This report  is the most comprehensive of its kind which focuses on the following areas:

• Chemotherapy, including -Subcategories Alkylating Agents, Antimetabolites, Cytotoxic Agents, Plant Derivatives

-Brands such as Elotaxin, Taxotere, Gemzar, Alimta and Temodar with Market Share for each

Hormone Therapy:

-Subcategories include Corticosteroids, Hormone Agonists/Antagonists, Aromatase Inhibitors and SERMS

-Brands such as Arimidex, Casodex, Zoladex, Femara and Lupron with Market Share for each.

Radiation Therapy: -Radiopharmaceuticals and Radioimmunotherapy categories

-Products including Bexxar, Theraseed and Zevalin

Immunotherapy and Biotherapy, including: -Monoclonal antibodies, interleukins/interferons, vaccines and other biotherapy

-Brands such as Rituxan, Herceptin, Gleevec, Evastin and Erbitux

Adjunctive Therapies, including:

-Antinauseants, Antiemetics, Pain Management Drugs and Biological Response Modifiers.

 

Few pharmaceutical markets will see the dramatic change that will occur in the market for cancer treatments over the next four years. More than $8 billion dollars worth of new products are expected in the next four years, impacting the treatment of cancer in ways that product managers, strategic planners, business development managers and marketing executives will need to be aware of.

Between 2004 and 2006, the market for cancer therapeutics saw more than an 18% increase, presaging future growth. Given the promising therapy pipeline and increasing incidence of cancer, double-digit growth is expected annually, leading to opportunities for current players and new entrants alike.

Kalorama's Cancer Therapeutics: The Worldwide Market is your guide to a $45 billion dollar cancer treatment market that is expected to double in the next four years. Kalorama’s detailed report includes the following:

• Complete Coverage of Cancer Treatment Markets in one complete volume.
• Over 6,160 Data Points of useful market data for business decisions.
• Current Market Size and Revenue Forecasts for each market segment for long-term strategic business planning.
• Round-Up of the Key Players in the Cancer Therapeutics Market
• The Collective Market Knowledge of over 65 Market Insiders interviewed for this report.
• Identification of the Fastest Growing Areas of Cancer Treatment so that marketers can make strategic adjustments or consider new products.
• Over 160 Tables and Figures for decision support and internal emails, memos and presentations.
• Discussion of 17 Issues and Trends critical to understanding this Market and assessing opportunities.

In this second edition, Kalorama builds on the success of the first edition of Cancer Therapeutics: The Worldwide Market, which correctly anticipated the growth of this market over the previous years. Since the last edition, there's been more changes in cancer treatment, especially in the area of immunobiological treatments for cancer. Kalorama details that change in this edition.

A truly global report, The Worldwide Market for Cancer Therapeutics breaks down the market for cancer therapeutics in the United States, Europe, Japan and the Rest of the World in detail.

The study focuses on current and emerging markets, products in development, and trends affecting the cancer treatment market. Demographic and epidemiological data are presented for the major cancer types, therapies in development are reviewed by development stage and earliest possible approval date, and profiles of the leading and significant competitors are included for reference. Therapeutics in the following areas are part of this report:

• Bladder
• Breast
• Cervical
• Colorectal
• Esophageal
• Head/Neck
• Kidney
• Leukemia
• Liver
• Lung
• Lymphoma
• Melanoma
• Multiple Myeloma
• Neuroblastoma
• Ovarian
• Pancreatic
• Prostate
• Stomach

As part of Kalorama's trusted information-gathering process, information for this report is drawn from company reports, government data and medical journals, then checked and cross-referenced extensively with experts in the cancer therapeutics industry. Interviews are the main source of market insights and forecasts.

Companies covered in this exhaustive report include:

• Amgen
• AstraZeneca plc
• Biogen IDEC, Inc.
• Bristol-Myers Squibb Company/Oncology
• Eli Lilly & Company
• Genentech, Inc.
• GlaxoSmithKline plc
• Johnson & Johnson Group
• Merck & Company, Inc.
• Novartis Pharmaceuticals
• Pfizer, Inc.
• Roche
• Sanofi-Aventis
• Schering-Plough
• TAP Pharmaceutical Products

Table of Contents

Chapter One: Executive Summary

• Introduction
• Scope and Methodology
• Size and Growth of the Market
• Issues and Trends Affecting the Market
• Leading Competitors

Chapter Two: Introduction

• What Is Cancer?
  • Biochemistry of Cancer Cells
  • Carcinogen Metabolism
  • Causes of Cancer Growth
    • Environmental Factors, DNA, RNA
    • Cellular Oncogenes
    • Tumor Suppressor Genes
• History and Growth of the Cancer Treatment Market
• Growth of Cancer Development
• Industry Structure
  • Product Segments and Technology
• Demographics and Statistics
• Description of Cancers
  • Bladder Cancer
  • Breast Cancer
  • Cervical Cancer
  • Colorectal Cancer
  • Esophageal Cancer
  • Head and Neck
  • Kidney
  • Leukemia
  • Liver
  • Lung Cancer
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Neuroblastoma
  • Ovarian Cancer
  • Pancreas
  • Prostate Cancer
  • Stomach Cancer

Chapter Three: Chemotherapy

• Overview
  • Alkylating Agents
    • Nitrogen Mustards
    • Cisplatin
  • Antimetabolites
    • Cytosine Arabinoside
    • 5-Fluorouracil (5-FU)
    • Hydroxyurea
    • Mercaptopurine and Thioguanine
    • Methotrexate
  • Cytotoxic Agents
    • Actinomycin D
    • Daunorubicin and Doxorubicin
    • Bleomycins
  • Plant Derivatives
    • Etoposide and Teniposide
    • Vincristine and Vinblastine
• Description of Products
  • Alkylating Agents
    • Nitrogen mustards
    • Nitrosoureas
    • Heavy metal compounds
    • Alkyl sulfonate
    • Ethylenimine
    • Triazene
  • Antimetabolites
    • Folic acid antagonist
    • Pyrimidine antagonists
    • Purine antagonists
  • Cytotoxic Agents
    • Daunorubicin (Cerubidine)
    • Doxorubicin (Adriamycin; Caelyx)
    • Idarubicin (Idamycin)
    • Bleomycin (Blenoxane)
    • Plicamycin (Mithramycin)
    • Mitomycin (Mitomycin-C)
    • Mitoxantrone HCl (Novantrone)
    • Dactinomycin (Cosmegen)
    • Valrubicin (Valstar)
  • Plant Derivatives
    • Vinblastine (Velban)
    • Vincristine (Oncovin)
    • Etoposide (Vesepid)
    • Paclitaxel (Taxol)
    • Docetaxel (Taxotere)
• Newly approved Chemotherapy Agents
• Research and Development
• Market Size and Growth
  • Markets by Product Type
  • Markets by Geographical Segments
    • U.S. Market
    • European Market
    • Japanese Market
    • ROW Market
  • Market Data by Indication
• Competitive Analysis

Chapter Four: Hormone Therapy

• Overview
  • Corticosteroids
  • Hormone Agonists and Antagonists
    • Estrogens
    • Androgens
    • Antiestrogens
    • Antiandrogens
    • Gonadotropin-releasing Hormone Analogues
  • Aromatase Inhibitors
  • Selective Estrogen Receptor Modulators (SERMs)
• Description of Products
  • Corticosteroids
    • Synthetic Corticosteroids
  • Hormone Agonists and Antagonists
    • Estrogen
    • Androgens
    • Antiandrogen
    • Antiestrogens
    • Gonadotropin Releasing Hormone Analogues
  • Aromatase Inhibitors
  • Selective Estrogen Receptor Modulators
• Newly Approved Cancer Hormone Therapy Drugs
• Research and Development
• Market Size and Growth
  • Markets by Product Type
  • Markets by Geographical Segments
    • U.S. Market
    • European Market
    • Japanese Market
    • ROW Market
  • Market Data by Indication
• Competitive Analysis

Chapter Five: Immunotherapy/Biotherapy

• Overview
  • Monoclonal Antibodies
  • Interleukins/Interferons
  • Vaccines
  • Other Biotherapy
    • Antisense Oligonucleotides
    • Apoptosis
    • Growth Factors
    • Methylation
    • P53
    • Ras Protein Drugs
    • Regulatory Enzymes
• Description of Products
  • Monoclonal Antibodies
    • Avastin (bevacizumab)
    • Campath (alemtuzumab)
    • Erbitux (cetuximab)
    • Herceptin (trastuzumab)
    • Mylotarg (gemtuzumab ozogamicin)
    • Panorex (edrecolomab)
    • Rituxan (rituximab)
  • Interleukins/Interferons
    • Alferon-N
    • Infergen
    • Intron A
    • Proleukin
    • Roferon A
  • Vaccines
    • Gardasil
    • M-Vax
    • Melacine
    • OncoTICE
    • OncoVax
    • Pacis
    • TheraCys (ImmuCyst)
  • Other Biotherapy
    • Enzyme Adenosine Deaminase
    • Tyrosine Kinases
    • Proteasome Inhibitors
• Newly Approved Immunotherapy Drugs
• Research and Development
• Market Size and Growth
  • Markets by Product Type
  • Markets by Geographical Segments
    • U.S. Market
    • European Market
    • Japanese Market
    • ROW Market
  • Market Data by Indication
• Competitive Analysis

Chapter Six: Radiation Therapy

• Overview
  • Types of Radiation Therapy
    • External Radiation
    • Internal Radiation
    • Systemic Radiation
  • Effects of Radiation
  • Radioactive Isotopes
• Description of Products
  • Radiopharmaceuticals
  • Radioimmunotherapy
    • Bexxar (tositumomab)
    • Zevalin (ibritumomab tiuxetan)
  • Other Radiation Therapy
    • Radioprotectants
    • Radiosensitizers
    • Radiotherapy Detection
• Research and Development
• Market Size and Growth
  • Markets by Product Type
  • Markets by Geographical Segments
    • U.S. Market
    • European Market
    • Japanese Market
    • ROW Market
  • Market Data by Indication
• Competitive Analysis

Chapter Seven: Adjunctive Therapies

• Overview
  • Nausea and Vomiting
  • Anemia and Related Symptoms
  • Infection Control
  • Pain Management
• Description of Products
  • Antinauseants and Antiemetics
    • Serotonin Receptor Antagonists
    • Phenothiazines
    • Metoclopramide and Other Drugs
  • Biological Response Modifiers
    • Hematopoetic Growth Factors
    • Cytomodulatory Agents
  • Pain Management
    • Narcotic Analgesics
    • Non-Narcotic Analgesics
  • Other Products
    • Mucositis Treatments
    • Bone Loss Treatments
• Newly Approved Cancer Adjunctive Therapies
• Research and Development
• Market Size and Growth
  • Markets by Product Type
  • Markets by Geographical Segments
    • U.S. Market
    • European Market
    • Japan Market
    • ROW Market
• Competitive Analysis

Chapter Eight: Total World Market and Forecast

• Overview
• Total market Size and Forecast
• Competitive Landscape

Chapter Nine: Issues and Trends

• Introduction
• Insurance and Reimbursement Issues
• Personalized Medicine
• Targeted Cancer Therapy
• Pharmacogenomics
• Marine-Derived Treatments
• Alliances Acquisitions and Licensing Agreements
• Patient-Reported Outcomes
• Cancer Drug Costs
• Marketing and Distribution Trends
• Immunogenicity
• Geographical Trends
  • United States
  • Europe
  • Japan
• Lifestyle and Social Issues
• Therapeutic Antibodies and Cancer Treatment
• Gene Therapy and Cancer Treatment
• Elderly Clinical trial involvement
  • Drug Development Trends
  • Early Detection and Screening
  • Comprehensive Research and Development

Chapter Ten: Corporate Profiles

• Introduction
• Amgen, Inc.
• AstraZeneca plc
• Biogen IDEC, Inc.
• Bristol-Myers Squibb Company/Oncology
• Eli Lilly & Company
• Genentech, Inc.
• GlaxoSmithKline plc
• Johnson & Johnson Group
• Merck & Company, Inc.
• Novartis Pharmaceuticals Corporation/Oncology
• Pfizer, Inc.
• Roche
• Sanofi-Aventis
• Schering-Plough Corporation
• Sanofi-Aventis
• TAP Pharmaceutical Products, Inc.

Appendix: Company Directory

 

LIST OF EXHIBITS

 

Chapter One: Executive Summary

• Table 1-1: World Cancer Therapies Market, 2004-2011 (in millions of dollars at the manufacturer’s level)
• Figure 1-1: World Cancer Therapies Market, 2004-2011 (in millions of dollars at the manufacturer’s level)

Chapter Two: Introduction

• Table 2-1: Viruses Associated with Cancer in Humans
• Table 2-2: Number of Cancer Therapy Approvals per Year in the United States, 1970-2006
• Figure 2-1: Number of Cancer Therapy Approvals per Year in the United States, 1970-2006
• Figure 2-2: Number of Cancer Therapies in Development, 2004-2006
• Table 2-3: Estimated and Projected World Cancer Incidence by Most Common Types of Cancer (Lung, Breast, Colon/Rectum, Stomach, Liver, Prostate, Cervical) 2005 and 2020
• Figure 2-3: Estimated and Projected World Cancer Incidence by Most Common Types of Cancer, 2005 and 2020
• Table 2-4: Estimated and Projected World Cancer Mortality by Most Common Types of Cancer, 2005 and 2020
• Figure 2-4: Estimated and Projected World Cancer Mortality by Most Common Types of Cancer, 2005 and 2020
• Table 2-5: Cancer Incidence and Mortality by Country 2005
• Figure 2-5: Cancer Incidence by Country 2005
• Figure 2-6: Cancer Deaths by Country 2005
• Table 2-6: Cancer Incidence and Deaths as a Percentage to Population by Selected Country/Region 2005
• Table 2-7: Total Cancer Incidence by Sex and Country, 2006 Estimates
• Figure 2-7: Total Cancer Incidence by Sex and Country
• Table 2-8: World Population by Selected Geographical Region (Africa, Asia, Europe, North America, Oceania, South America) 2006-2050
• Figure 2-8: World Population by Selected Geographical Region, 2006-2050
• Table 2-9: Estimated World Population by Age and Geographical Region, 2006 (in millions)
• Figure 2-9: Estimated World Population by Age and Geographical Region, 2006
• Table 2-10: Life Expectancy at Birth by Selected Countries (11 Countries), Projected 2006
• Table 2-11: United States Life Expectancy at Birth, 1990 and 2000; Projections, 2006 and 2010
• Figire 2-10: United States Average Years of Life Lost Per Person Dying of Cancer, All Races, Both Sexes, 2002
• Figure 2-11: United States Estimated Person-Years of Life Lost Due to Cancer, All Races, Both Sexes, 2003
• Figure 2-12: Approved Cancer Therapies in the United States by Indication
• Table 2-12: Types of Luekemia
• Table 2-13: Types of Primary Lung Cancer
• Table 2-14: Classification of Non-Hodgkin’s Lymphomas
• Table 2-15: Malignant Conditions of the Skin
• Table 2-16: Estimated World and U.S. Incidence and Mortality of Cancer (in thousands)
• Figure 2-13: Estimated World and U.S. Incidence and Mortality of Cancer (thousands)

Chapter Three: Chemotherapy

• Table 3-1: Alkylating Agents
• Table 3-2: Antimetabolites
• Table 3-3: Cytotoxic Agents
• Table 3-4: Plant Derivatives
• Table 3-5: Newly Approved Chemotherapy Agents
• Table 3-6: Chemotherapy Drugs in Late Stage Development (Product, Developer, Phase, Cancer Type and Earliest Approval Date)
• Table 3-7: World Chemotherapy Market, 2004-2011 (in millions of dollars at the manufacturers level)
• Figure 3-1: World Chemotherapy Market, 2004-2011 (in millions of dollars at the manufacturers level)
• Table 3-8: World Chemotherapy Market Market by Product Type (Alkylating Agents, Antimetabolites, Cytotoxic Agents and Plant Derivatives), 2004-2011
• Figure 3-2: World Chemotherapy Market Market by Product Type Revenues, 2004-2011 (in millions at the manufacturers level)
• Figure 3-3: World Chemotherapy Market Market by Product Type and Percent Distribution, 2004 -2011
• Figure 3-4: World Chemotherapy Market Market by Product Type and Percent Market Share, 2006
• Figure 3-5: World Chemotherapy Market Market by Product Type and Percent Market Share, 2011
• Table 3-9: World Chemotherapy Market Estimated Products Sales by Region, 2004-2011 (in million of dollars at the manufacturers level) Estimated Revenues
• Figure 3-6: World Chemotherapy Market Estimated Product Sales by Region, 2004-2011 (in millions at the manufacturers level)
• Figure 3-7: World Chemotherapy Market Estimated Products Sales by Region, 2006
• Figure 3-8: World Chemotherapy Market Estimated Products Sales by Region, 2011
• Table 3-10: World Chemotherapy Market Estimated Products Sales and Percent of Market by Cancer Type, 2006 (in million of dollars at the manufacturers level)
• Figure 3-9: World Chemotherapy Market Estimated Products Sales by Cancer Type, 2006
• Table 3-11: World Chemotherapy Market Leading Suppliers Shares by Market Revenues, Estimated 2006 and Projected 2011 (in million of dollars at the manufacturers level)
• Figure 3-10: World Chemotherapy Market Leading Suppliers Market Share, Estimated 2006
• Figure 3-11: World Chemotherapy Market Leading Suppliers Market Share, Projected 2011
• Table 3-12: World Chemotherapy Market Top Chemotherapy Products by Estimated Sales and Percent of Market, 2006 (in million of dollars at the manufacturers level)
• Figure 3-12: World Chemotherapy Market Top Chemotherapy Products by Estimated Sales and Percent of Market, 2006

Chapter Four: Hormone Therapy

• Table 4-1: Corticosteroids
• Table 4-2: Hormone Agonists and Antagonists
• Table 4-3: Aromatase Inhibitors
• Table 4-4: Selective Estrogen Receptor Modulators
• Table 4-5: Newly Approved Cancer Hormone Therapy Agents
• Table 4-6: Cancer Hormone Therapy in Late Stage Development (Developer, Phase, Cancer Type and Earliest Approval Date)
• Table 4-7: World Hormone Therapy Market, 2004-2011 (in millions of dollars at the manufacturers level)
• Figure 4-1: World Hormone Therapy Market, 2004-2011 (in millions of dollars at the manufacturers level)
• Table 4-8: World Hormone Therapy Market Market by Product Type (Corticosteroids, Hormone Agonist/Antagonists, Aromatase Inhibitors and SERMS) 2004-2011
• Figure 4-2: World Hormone Therapy Market Market by Product Type Revenues, 2004-2011 (in millions at the manufacturers level)
• Figure 4-3: World Hormone Therapy Market Market by Product Type and Percent Distribution, 2004-2011
• Figure 4-4: World Hormone Therapy Market Market by Product Type and Percent Market Share, 2006
• Figure 4-5: World Hormone Therapy Market Market by Product Type and Percent Market Share, 2011
• Table 4-9: World Hormone Therapy Market Estimated Products Sales by Region, 2004-2011 (in million of dollars at the manufacturers level) Estimated Revenues
• Figure 4-6: World Hormone Therapy Market Estimated Product Sales by Region, 2004-2011 (in millions at the manufacturers level)
• Figure 4-7: World Hormone Therapy Market Estimated Products Sales by Region, 2006
• Figure 4-8: World Hormone Therapy Market Estimated Products Sales by Region, 2011
• Table 4-10: World Hormone Therapy Market Estimated Products Sales by Cancer Type (Breast, Prostate and Other Cancers), 2006 (in million of dollars at the manufacturers level)
• Figure 4-9: World Hormone Therapy Market Estimated Products Sales by Cancer Type, 2006
• Table 4-11: World Hormone Therapy Market Leading Suppliers Shares by Market Revenues, Estimated 2006 and Projected 2011 (in million of dollars at the manufacturers level)
• Figure 4-10: World Hormone Therapy Market Leading Suppliers Market Share, Estimated 2006
• Figure 4-11: World Hormone Therapy Market Leading Suppliers Market Share, Projected 2011
• Table 4-12: Top Hormone Therapy Products by Estimated World Sales and Percent of World Market, 2006 (in million of dollars at the manufacturers level)
• Figure 4-13: World Hormone Therapy Market Top Hormone Therapy Products by Estimated Sales and Percent of Market, 2006

Chapter Five: Immunotherapy/Biotherapy

• Table 5-1: Monoclonal Antibodies
• Table 5-2: Interleukin/Interferon
• Table 5-3: Vaccines
• Table 5-4: Other Biotherapy
• Table 5-5: Newly Approved Immunotherapy/Biologic Agents
• Table 5-6: Cancer Immunotherapy and Biotherapy Products in Late Stage Development (Product, Developer, Current Phase, Cancer Type, and Earliest Approval Date)
• Table 5-7: World Cancer Immunotherapy Market, 2004-2011 (in millions of dollars at the manufacturers level)
• Figure 5-1: World Cancer Immunotherapy Market, 2004-2011 (in millions of dollars at the manufacturers level)
• Table 5-8: World Cancer Immunotherapy Market; Market by Product Type (Monoclonal Antibodies, Interleukins/Interferons, Vaccines and Other Biotherapy), 2004-2011
• Figure 5-2: World Cancer Immunotherapy Market Market by Product Type Revenues, 2004-2011 (in millions at the manufacturers level)
• Figure 5-3: World Cancer Immunotherapy Market Market by Product Type and Percent Distribution, 2004-2011
• Figure 5-4: World Cancer Immunotherapy Market Market by Product Type and Percent Market Share, 2006
• Figure 5-5: World Cancer Immunotherapy Market Market by Product Type and Percent Market Share, 2011
• Table 5-9: World Cancer Immunotherapy Market Estimated Products Sales by Region (U.S., Europe, Japan, Rest of World), 2004-2011 (in million of dollars at the manufacturers level) Estimated Revenues
• Figure 5-6: World Cancer Immunotherapy Market Estimated Product Sales by Region, 2004-2011 (in millions at the manufacturers level)
• Figure 5-7: World Cancer Immunotherapy Market Estimated Products Sales by Region, 2006
• Figure 5-8: World Cancer Immunotherapy Market Estimated Products Sales by Region, 2011
• Table 5-10: World Cancer Immunotherapy Market Estimated Products Sales by Cancer Type, 2006 (in million of dollars at the manufacturers level)
• Figure 5-9: World Cancer Immunotherapy Market Estimated Products Sales by Cancer Type, 2006
• Table 5-11: World Cancer Immunotherapy Market Leading Suppliers Shares by Market Revenues, Estimated 2006 and Projected 2011 (in million of dollars at the manufacturers level)
• Figure 5-10: World Cancer Immunotherapy Market Leading Suppliers Market Share, Estimated 2006
• Figure 5-11: World Cancer Immunotherapy Market Leading Suppliers Market Share, Projected 2011
• Table 5-12: World Cancer Immunotherapy Market Top Cancer Immunotherapy Products by Estimated Sales and Percent of Market, 2006 (in million of dollars at the manufacturers level)
• Figure 5-12: World Cancer Immunotherapy Market Top Cancer Immunotherapy Products by Estimated Sales and Percent of Market, 2006

Chapter Six: Radiation Therapy

• Table 6-1: Radiopharmaceuticals
• Table 6-2: Radioimmunotherapy
• Table 6-3: Cancer Radiation Therapies in Late Stage Development (Product, Developer, Phase, Cancer Type, Earliest Approval Date)
• Table 6-4: World Cancer Radiation Therapy Market, 2004-2011 (in millions of dollars at the manufacturers level)
• Figure 6-1: World Cancer Radiation Therapy Market, 2004-2011 (in millions of dollars at the manufacturers level)
• Table 6-5: World Cancer Radiation Therapy Market Market by Product Type: Radiopharmaceuticals and Radioimmunotherapy, 2004-2011 (in millions of dollars at the manufacturers level)
• Figure 6-2: World Cancer Radiation Therapy Market Market by Product Type Revenues, 2004-2011 (in millions at the manufacturers level)
• Figure 6-3: World Cancer Radiation Therapy Market Market by Product Type and Percent Distribution, 2004-2011
• Figure 6-4: World Cancer Radiation Therapy Market Market by Product Type and Percent Market Share, 2006
• Figure 6-5: World Cancer Radiation Therapy Market Market by Product Type and Percent Market Share, 2011
• Table 6-6: World Cancer Radiation Therapy Market Estimated Products Sales by Region, 2004-2011 (in million of dollars at the manufacturers level) Estimated Revenues
• Figure 6-6: World Cancer Radiation Therapy Market Estimated Product Sales by Region, 2004-2011 (in millions at the manufacturers level)
• Figure 6-7: World Cancer Radiation Therapy Market Estimated Products Sales by Region, 2006
• Figure 6-8: World Cancer Radiation Therapy Market Estimated Products Sales by Region, 2011
• Table 6-7: World Cancer Radiation Therapy Market Estimated Products Sales by Cancer Type, 2006 (in million of dollars at the manufacturers level)
• Figure 6-9: World Cancer Radiation Therapy Market Estimated Products Sales by Cancer Type, 2006
• Table 6-8: World Cancer Radiation Therapy Market Leading Suppliers Shares by Market Revenues, Estimated 2006 and Projected 2011 (in million of dollars at the manufacturers level)
• Figure 6-10: World Cancer Radiation Therapy Market Leading Suppliers Market Share, Estimated 2006
• Figure 6-11: World Cancer Radiation Therapy Market Leading Suppliers Market Share, Projected 2011
• Table 6-9: World Cancer Radiation Therapy Market Top Cancer Radiation Therapy Products by Estimated Sales and Percent of Market, 2006 (in million of dollars at the manufacturers level)
• Figure 6-12: World Cancer Radiation Therapy Market Top Cancer Radiation Therapy Products by Estimated Sales and Percent of Market, 2006

Chapter Seven: Adjunctive Therapies

• Table 7-1: Side Effects Associated with Chemotherapy
• Table 7-2: Side Effects Associated with Radiation Therapy
• Figure 7-1: Incidence of Emesis in Cancer Patients
• Table 7-3: Chemotherapy Agents and Level of Emetic Potential
• Figure 7-2: Incidence of Bone Marrow Suppression in Cancer Patients
• Table 7-4: Common Infection Sites
• Figure 7-3: Incidence of Infection in Cancer Patients
• Figure 7-4: Incidence of Pain in Cancer Patients
• Table 7-5: Antinauseants and Antiemetics
• Table 7-6: Biological Response Modifiers
• Table 7-7: Cancer Pain Management
• Table 7-8: Other Adjunctive Treatments
• Table 7-9: Newly Approved Adjunctive Agents
• Table 7-10: Cancer Adjunctive Therapies in Late Stage Development (Product, Developer, Phase, Indication, Earliest Approval Date)
• Table 7-11: World Cancer Adjunctive Therapy Market, 2004-2011 (in millions of dollars at the manufacturers level)
• Figure 7-5: World Cancer Adjunctive Therapy Market, 2004-2011 (in millions of dollars at the manufacturers level)
• Table 7-12: World Cancer Adjunctive Therapy Market Market by Product Type, 2004-2011
• Figure 7-6: World Cancer Adjunctive Therapy Market Market by Product Type Revenues, 2004-2011 (in millions at the manufacturers level)
• Figure 7-7: World Cancer Adjunctive Therapy Market Market by Product Type and Percent Distribution, 2004-2011
• Figure 7-8: World Cancer Adjunctive Therapy Market Market by Product Type and Percent Market Share, 2006
• Figure 7-9: World Cancer Adjunctive Therapy Market Market by Product Type and Percent Market Share, 2011
• Table 7-13: World Cancer Adjunctive Therapy Market Estimated Products Sales by Region, 2004-2011 (in million of dollars at the manufacturers level) Estimated Revenues
• Figure 7-10: World Cancer Adjunctive Therapy Market Estimated Product Sales by Region, 2004-2011 (in millions at the manufacturers level)
• Figure 7-11: World Cancer Adjunctive Therapy Market Estimated Products Sales by Region, 2006
• Figure 7-12: World Cancer Adjunctive Therapy Market Estimated Products Sales by Region, 2011
• Table 7-14: World Cancer Adjunctive Therapy Market Leading Suppliers Shares by Market Revenues, Estimated 2006 and Projected 2011 (in million of dollars at the manufacturers level)
• Figure 7-13: World Cancer Adjunctive Therapy Market Leading Suppliers Market Share, Estimated 2006
• Figure 7-14: World Cancer Adjunctive Therapy Market Leading Suppliers Market Share, Projected 2011

Chapter Eight: Total World Market and Forecast

• Table 8-1: World Cancer Therapies Market, 2004-2011 (in millions of dollars at the manufacturers level)
• Figure 8-1: World Cancer Therapies Market, 2004-2011 (in millions of dollars at the manufacturers level)
• Table 8-2: World Cancer Therapies Market, 2004-2011
• Figure 8-2: World Cancer Therapies Market Market Revenues and Percent Distribution, 2002-2009 (in millions at the manufacturers level)
• Figure 8-3: World Cancer Therapies Market Market by Percent, 2006
• Figure 8-4: World Cancer Therapies Market Market by Percent, 2011

Chapter Nine: Issues and Trends

• Table 9-1: Cancer Detection Tests
• Table 9-2: Cancer Research and Development (Product, Developer, Current Devolpment Phase, Cancer Type)

Chapter Ten: Corporate Profiles

• Figure 10-1: Cancer Therapies in Development by Leading Company

Other users found this report page using the following search terms: Chemotherapy Alkylating Agents Antimetabolites Cytotoxic Agents Hormone Therapy Aromatase Inhibitors SERMS Radiation Therapy Immunotherapy vaccines market cancer size worldwide sales therapeutics oncology chemotherapy therapy share

If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.